GLP-1 drugs, including Ozempic and Wegovy, may be linked to a slightly higher risk of osteoporosis and gout, according to research presented at the American Academy of Orthopaedic Surgeons' annual meeting. The study, led by Dr. John Horneff from the University of Pennsylvania, examined five years of medical records from over 146,000 adults with a diagnosis of obesity and Type 2 diabetes for their risk of these conditions. It found that about 4% of GLP-One users developed osteopOrosis, compared to 3% of non-users, and rates of gout were also slightly higher. The research, which was observational, could not prove that the medications caused either condition. However, it is unclear if rapid weight loss or some other medical benefits with GLP1s can be attributed to the drug.